How Cosentyx Works on the Immune System
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine driving inflammation in autoimmune conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. By blocking IL-17A, it reduces immune overactivity in skin and joints, easing symptoms.[1]
Short-Term Immune Effects
In clinical trials, Cosentyx quickly lowers inflammatory markers like C-reactive protein within weeks. It suppresses Th17 cells, which produce IL-17A, without broadly depleting immune cells like T cells or B cells. Patients see fewer infections early on, but upper respiratory infections occur in 10-20% of users, similar to placebo in some studies.[2][3]
Long-Term Effects on Immunity (Up to 5 Years)
Over 5 years in extension trials (e.g., SCULPTURE for psoriasis), Cosentyx maintains efficacy with sustained IL-17A blockade. No evidence shows progressive immune weakening; T-cell counts and antibody responses to vaccines (like flu or pneumococcal) remain intact.[4] Real-world data from registries like BADBIRD (over 1,000 patients) report stable infection rates, with serious infections in under 2% annually.[5]
Observed Long-Term Risks
Common infections persist long-term: nasopharyngitis (14%), upper respiratory tract infections (10-15%). Opportunistic infections like candidiasis rise slightly (3-5%) due to IL-17's antifungal role, but rates stabilize.[6] No increased tuberculosis reactivation in screened patients; IBD flares occur rarely (0.1-0.4%). Malignancy risk matches general population after 4-5 years.[7] No cumulative immunosuppression like with TNF inhibitors.
Comparisons to Other Biologics
Unlike TNF blockers (e.g., Humira), which broadly dampen immunity and raise serious infection risk by 20-30%, Cosentyx's targeted IL-17 inhibition shows lower long-term infection odds (odds ratio 1.2 vs. 1.5-2.0 for TNFs).[8] Versus IL-23 inhibitors (e.g., Tremfya), infection profiles align closely, but Cosentyx has more candidiasis data from longer use.[9]
Patient Monitoring and Reversibility
Immunity rebounds after stopping; IL-17A levels normalize within months, with no lasting deficits in trials.[10] Guidelines recommend screening for TB/latents before starting and monitoring infections yearly. Vaccinate before therapy—live vaccines avoided during treatment.[11]
[1] https://www.cosentyx.com
[2] Langley RG et al., N Engl J Med 2014
[3] FDA Label, Cosentyx
[4] Bissonnette R et al., J Am Acad Dermatol 2018
[5] Torres T et al., Acta Derm Venereol 2020
[6] McInnes IB et al., Lancet 2015 (MEASURE trials)
[7] Papp K et al., J Eur Acad Dermatol Venereol 2021
[8] Mariette X et al., Ann Rheum Dis 2018 meta-analysis
[9] Gordon KB et al., Lancet 2018 (IL-23 comparison)
[10] van de Kerkhof P et al., Br J Dermatol 2016
[11] American College of Rheumatology Guidelines 2021